XM
ATXS

XTX Markets’s Astria Therapeutics ATXS Stock Holding History

XTX Markets’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$56K Buy
+4,340
New +$77.3K 0.12% 179

Other funds holding ATXS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

XTX Markets's ATXS Position: Q4 2020 in Review

XTX Markets opened a new position in Astria Therapeutics (ATXS) in Q4 2020: 4,340 shares worth $56K. The stake represents 0.12% of the portfolio and ranks #179 among its holdings.

62 funds tracked by Wall St. Rank hold ATXS as of Q4 2020.

  • XTX Markets held 4,340 shares of Astria Therapeutics worth $56K as of Q4 2020.
  • Astria Therapeutics was a new XTX Markets position in Q4 2020.
  • Astria Therapeutics made up 0.12% of XTX Markets's portfolio in Q4 2020, its #179 holding.
  • 62 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2020.

Based on XTX Markets's 13F filing for Q4 2020, filed 25 Jan 2021.